secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001213900-23-011512
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne Q1 FY2023 net loss $1.7M; FDA cleared Evo sEEG electrode
-----------------------------------------------------------------

- Product revenue $115K (vs $34K YoY); collaboration revenue $1.46M from Zimmer agreement.
- Net loss $1.7M (improved from $2.8M); cash $7.6M, no debt as of Dec 31, 2022.
- FDA 510(k) clearance for Evo sEEG electrode; first commercial order shipped to Zimmer Biomet.
- Targeting OneRF ablation system 510(k) submission in Q2 calendar 2023; spinal cord stimulation electrodes in pre-clinical.
- R&D expense $1.6M (up from $1.1M); SG&A flat at $1.7M; total op ex $3.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390023011512/0001213900-23-011512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390023011512/ea173234-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-011512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer